NTRAHealthcare · Diagnostics & ResearchThe 23 Wall Street analysts covering Natera, Inc. hold a median 12-month price target of $362 — -8.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 6 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Natera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NTRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −8.5% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | Citigroup | Maintains | Buy | $365 → $480 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $360 → $475 |
| 25 Sept 2026 | RBC Capital | Maintains | Outperform | $350 → $460 |
| 9 Sept 2026 | UBS | Maintains | Buy | $290 → $435 |
| 9 Sept 2026 | UBS | Maintains | Buy | — |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | $385 |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | — |
| 13 Aug 2026 | Citigroup | Maintains | Buy | $315 → $365 |
| 13 Aug 2026 | Citigroup | Maintains | Buy | — |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | $290 → $360 |
| 12 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 12 Aug 2026 | Piper Sandler | Maintains | Overweight | $249 → $364 |
| 12 Aug 2026 | Stephens & Co. | Maintains | Overweight | $305 → $350 |
| 12 Aug 2026 | Stephens & Co. | Maintains | Overweight | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | $290 → $320 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | — |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $300 → $315 |
| 7 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTRA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Natera, Inc. returned +134.7% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 9% of US stocks
Cheaper than 3% of US stocks
Cheaper than 98% of US stocks
Higher than 82% of US stocks
Higher than 78% of US stocks
Higher than 24% of US stocks
Higher than 22% of US stocks
Higher than 35% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Natera, Inc. has a market value of $61.4B and an enterprise value of $60.5B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 37.7% year on year.
Net income over the same four quarters: −$192.3M, a −7.1% net margin.
Free cash flow in the twelve months to 30 June 2026: $51.2M.
Trailing P/E: −261.6×; forward P/E: −2893.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Natera, Inc. employs 6,135 people — $441K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Natera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Natera announced that the first patients have enrolled in a NYU Langone Health-sponsored randomized, Signatera-guided trial in advanced or metastatic melanoma. The study uses Signatera to guide treatment escalation.
Why it matters — The trial expands the reported use of Natera’s Signatera test into a melanoma treatment-guidance study.
Natera announced new Signatera data presented at the ASTRO 2026 Annual Meeting, its first participation at the conference. All four abstracts were selected for oral presentation and addressed Signatera's role in treatment-response monitoring and risk stratification.
Why it matters — The presentations highlight clinical applications of Signatera relevant to radiation oncologists and broaden the company's visibility at a major oncology meeting.
Alliance Foundation Trials and Natera announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a molecular residual disease (MRD)-guided treatment strategy using Signatera for patients with intermediate- and high-risk ER-positive/HER2-negative early breast cancer. The trial will test Genentech's oral SERD alongside Signatera-guided CDK4/6 inhibitor therapy.
Why it matters — This expands the clinical evidence base for Natera's Signatera test to guide treatment decisions in early breast cancer, a potential new application for the company's MRD platform.
ETF Trends reports that strong performance in the healthtech sector over the past two quarters has renewed market interest in medical innovation. In response to a high volume of inquiries, the publication compiled a guide answering the most frequent and interesting questions about its Healthcare Technology and Innovation Index (HTEC).
Why it matters — As a healthtech company, Natera could be relevant to the sector's renewed market attention and to investors following healthtech indices like HTEC.
Natera received Japan PMDA approval for its Signatera test in muscle-invasive bladder cancer, where it will support treatment decisions ahead of a planned 2027 commercial launch in Japan.
Why it matters — The approval expands Signatera's regulatory footprint into a new international market and adds a bladder cancer indication, broadening Natera's addressable use cases.
The 23 Wall Street analysts covering Natera, Inc. have a median 12-month price target of $362, with estimates ranging from $280 to $475. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Natera, Inc., 21 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Natera, Inc. 80 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Natera, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies -8.5% from the last close, and Ticker Nerd's factor model ranks Natera, Inc. 80 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Natera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $475 over the next 12 months.
Natera, Inc. returned +134.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use.
The most recent item we track (Business Wire, 7 Oct 2026): "Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma". Natera announced that the first patients have enrolled in a NYU Langone Health-sponsored randomized, Signatera-guided trial in advanced or metastatic melanoma. The study uses Signatera to guide treatment escalation.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
CEO Mr. Steven Leonard Chapman · 6,135 employees · United States · https://www.natera.com
